BOCA RATON, Fla., July 27, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in...
NORCROSS, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins,...
BOCA RATON, Fla., July 26, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in...
Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced...
€4 million ($4.2 million) research and innovation award for consortium to develop first-in-class smart bioprocessing manufacturing platformLONDON, July 21, 2022...
Research will leverage Artizan’s proprietary IgA-SEQ™ discovery platform to identify gut microbiota that may affect the safety and efficacy of...
--6th Orphan Drug Designation granted to toripalimab in the US and EU SHANGHAI, China, July 21, 2022 (GLOBE NEWSWIRE) --...
ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs’ Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA...
Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study Proposed Hyrimoz® HCF would help expand...
Portage now holds 100% ownership of iOx Therapeutics Ltd., buying out remainder of equity in exchange for PRTG stockWESTPORT, Conn.,...
Ad hoc announcement pursuant to Art. 53 LR Q2 sales grew +5% cc1 (-1% USD) Innovative Medicines (IM) sales grew...
Intratumoral injection of allogeneic pro-inflammatory dendritic cells (“ilixadencel”) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in...
CV8102 recommended dose identified; expansion trial to confirm safety, tolerability, and efficacy Trial expansion focuses on advanced melanoma, an indication of...